Andrew J Murphy's Stock Transactions in Regeneron Pharmaceuticals

Andrew J Murphy, EVP Research at Regeneron Pharmaceuticals, Inc., reported several transactions involving the company's common stock and stock options. On October 29, 2025, Murphy acquired 35,000 shares of common stock at $555.67 per share and disposed of 32,490 shares at $648.82 per share. Additionally, he exercised 35,000 non-qualified stock options, resulting in the acquisition of 35,000 shares of common stock at $555.67 per share. On October 30, 2025, Murphy disposed of 1,538 shares of common stock. Following these transactions, Murphy's direct ownership in Regeneron Pharmaceuticals stood at 50,046 shares, and he held 4,370 shares indirectly through a 401(k) plan. The stock option award vested in four equal annual installments, commencing one year after the date of grant.